Sono-Tek Corporation — Form 10-Q Summary
Reporting period: Three months ended May 31, 2016, the first quarter of fiscal 2017. Sono-Tek develops, manufactures, sells, installs, and services ultrasonic spray-coating equipment worldwide, and also operates rental real estate. Financial statements are unaudited.
Financial performance and position
| Metric | Quarter ended May 31, 2016 | Prior-year quarter | Change |
|---|---|---|---|
| Net sales | $2.240 million | $2.883 million | Down 22% |
| Gross profit / margin | $1.023 million / 45.7% | $1.373 million / 47.6% | Down $350,000; margin declined about 1.9 percentage points |
| Operating income (loss) | ($140,000) | $223,000 | Decreased $363,000 |
| Net income | $56,000 | $154,000 | Down 64% |
| Basic and diluted EPS | $0.00 | $0.01 | Lower |
| Net cash from operating activities | $439,000 | $292,000 | Up $147,000 |
Quarter-end cash and cash equivalents were $2.636 million, and marketable securities were $1.808 million, totaling $4.444 million. Management reported working capital of $5.960 million and a current ratio of 5.1 to 1. Total assets were $10.558 million and stockholders’ equity was $7.787 million.
Total debt was $1.284 million, including $138,000 current and $1.147 million long-term, under a bank note bearing 4.15% interest and secured by land and buildings. The $750,000 revolving credit line had no borrowings at quarter-end. Investing activities used $156,000, primarily for $94,000 of equipment and $62,000 of marketable securities purchases. Financing activities used $36,000 for debt repayments. Cash increased $247,000 during the quarter.
Changes versus the prior-year quarter
- Ultrasonic spraying sales fell 22% to approximately $2.216 million. Management cited lower sales of WideTrack and stent-coating units, partly offset by higher XYZ platform sales; declines were concentrated in Asian and Latin American markets and in float glass, stent coating, and fluxer product lines.
- Gross margin declined as sales of higher-margin WideTrack and stent-coating units decreased. Improved fluxer and spare-parts margins and lower installation costs partly offset the impact.
- Operating expenses rose modestly to $1.163 million. Research and product development increased 8%, while marketing and selling expense fell 4% and general and administrative expense increased 5%.
- Operating results deteriorated from income to a loss. Net income was supported by approximately $200,000 of life-insurance proceeds following the death of a former employee; without this unusual other income, the reported bottom line would have been materially weaker.
- Operating cash flow improved, helped by a $396,000 reduction in accounts receivable. Cash and marketable securities together increased $360,000 from February 29, 2016.
Outlook, commentary, and risks
Based on its current backlog, management expected sales for the quarter ending August 31, 2016, to be comparable to the May quarter. The filing gives no quantified full-year revenue or earnings guidance. Management described new products and broader industry and geographic reach as a basis for future growth, and noted recent completion of the SPT200 and SonoBraze products.
Results remain exposed to fluctuating demand and order timing, market and economic conditions, competition, timely product development and acceptance, financing adequacy, and the ability to increase sales and sustain profitability. Management cautioned that interim results are not necessarily indicative of full-year results. The filing reported no legal proceedings and no material changes to internal control over financial reporting; management concluded disclosure controls were effective.
Important facts for investors to verify
- Whether the sales decline and weaker product mix persist, particularly in the Asian and Latin American markets and the float-glass, stent-coating, and fluxer lines.
- How much of reported net income depended on the approximately $200,000 life-insurance proceeds, and the related accounting and tax treatment.
- Whether the backlog supports management’s expectation of comparable sales in the August 2016 quarter, and whether recently completed products generate commercial demand.
- The sustainability of operating cash flow, including the contribution from collecting receivables, and planned equipment spending and debt repayments.
- The filing reports the quarter’s unrealized securities gain in other comprehensive income and an ending accumulated other comprehensive loss of $14,199; confirm investment valuation and related disclosures when reviewing the complete filing.